CTOs on the Move

Casma Therapeutics

www.casmatx.com

 
New discoveries are revealing the fundamental role of autophagy and lysosomal flux in maintaining cellular health. Furthermore, it is now appreciated that inadequate or aberrant autophagy contributes to a wide range of diseases. We are focused on boosting autophagy – pioneering novel therapeutic strategies to address unmet medical needs. We are creating a new target set for drug discovery and development, and advancing innovative paradigms to treat a broad set of illnesses that are either neglected or inadequately addressed today. Our growing team is driven to transform fundamental discoveries on autophagy into promising therapeutic medicines.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Casma Therapeutics raised $58.5M on 05/03/2018
Casma Therapeutics raised $50M on 09/10/2020

Similar Companies

Vivakor

Vivakor is a Coralville, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Molecular Therapeutics

Molecular Therapeutics is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Biosearch Technologies

Biosearch Technologies is a Novato, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Amarantus

Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. The Company has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready indication for Parkinson's Levodopa induced dyskinesia and Adult ADHD. The Company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test(R)") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders.   Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard").

ValenzaBio

ValenzaBio is a privately-held biopharmaceutical company developing therapies for autoimmune and inflammatory diseases. With a pipeline of differentiated monoclonal antibodies targeting clinically-validated mechanisms of action, we seek to provide improved therapies for patients with limited treatment options. Based in Bethesda, Maryland, in the heart of the capital biotech community, we strive to work collaboratively with all stakeholders while keeping our research and development efforts focused on the needs of patients.